PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 16, 2026

IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

LČLuka ČavkaSNSubhiksha NandakumarQWQingqing Wu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows IDH1 mutations enhance survival in prostate cancer, suggesting potential subclass benefits.

Key Points

  • This research aims to explore the clinical features and outcomes associated with IDH1 and IDH2 mutations in prostate cancer.
  • Conducted a retrospective analysis of 99 IDH1 and 12 IDH2 mutated cases from genomics databases across multiple institutions.
  • Established a matched control cohort of IDH wild-type prostate cancer cases with similar clinical features at diagnosis.
  • Evaluated overall survival, metastasis-free survival, and progression-free survival on hormonal therapy.
  • IDH1 mutations were associated with significantly longer overall survival (HR 0.16, 95% CI 0.04-0.68, p=0.01).
  • Patients with IDH1 mutations demonstrated longer metastasis-free survival (HR 0.22, 95% CI 0.09-0.58, p=0.002).
  • Progression-free survival on hormonal therapy was also prolonged for IDH1-mutant cases (HR 0.35, 95% CI 0.16-0.76, p=0.036).

Cite This Study

Čavka et al. (2026) studied this question.

synapsesocial.com/papers/6a080b17a487c87a6a40d199https://doi.org/10.1016/j.eururo.2026.03.014
View Full Paper
Ask AI
Bookmark
Share